Valuation : Opus Genetics, Inc.

Market Cap 477M 410M 386M 352M 658M 45.36B 661M 4.58B 1.77B 23.11B 1.79B 1.75B 73.21B P/E 2026 *
-5.85x
P/E 2027 * -8.09x
Enterprise Value 477M 410M 386M 352M 658M 45.36B 661M 4.58B 1.77B 23.11B 1.79B 1.75B 73.21B EV / Sales 2026 *
36.4x
EV / Sales 2027 * 35.1x
Free-Float
89.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Opus Genetics, Inc.

1 day+2.09%
1 week+26.30%
Current month+60.50%
1 month+58.74%
3 months+49.36%
6 months+19.79%
Current year+189.05%
1 week 4.3
Extreme 4.305
7.07
1 month 3.51
Extreme 3.511
7.07
Current year 1.88
Extreme 1.88
7.07
1 year 1.32
Extreme 1.32
7.07
3 years 0.65
Extreme 0.65
7.07
5 years 0.65
Extreme 0.65
7.07
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 01/11/2023
Director of Finance/CFO 52 02/09/2025
President 60 22/10/2024
Director TitleAgeSince
Director/Board Member 77 01/11/2020
Chairman 56 01/12/2019
Director/Board Member 59 01/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/26 Exercice

Chairman

1,568,628 1.8855%
3/9/26 Sell

Chief Financial Officer

-28,000 0.0337%
23/7/26 Sell

Chief Financial Officer

-7,783 0.0094%
Change 5-day change 1-year change 3-year change Capi.($)
+2.53%+26.30%+336.84%+43.46% 477M
+0.10%-2.77%+49.40%+89.31% 1,002B
+0.08%-3.31%+53.14%+65.50% 644B
+0.51%-2.73%+19.59%+69.82% 443B
-0.86%-3.34%+29.50%+35.72% 343B
+0.36%-14.47%+11.49%+27.19% 262B
+0.33%-3.84%-1.96%+11.22% 245B
-0.80%-12.54%+39.46%+48.41% 212B
-0.81%-5.04%-18.45%-58.13% 199B
-0.82%-4.42%+25.41%+87.60% 181B
Average -0.01%-1.62%+54.44%+42.01% 353.02B
Weighted average by Cap. -0.09%-4.24%+32.43%+56.45%

Financials

2026 *2027 *
Net sales 13.11M 11.28M 10.62M 9.68M 18.11M 1.25B 18.18M 126M 48.66M 636M 49.23M 48.16M 2.01B 13.59M 11.7M 11.01M 10.04M 18.78M 1.29B 18.85M 131M 50.45M 659M 51.05M 49.94M 2.09B
Net income -91.93M -79.1M -74.48M -67.87M -127M -8.75B -127M -883M -341M -4.46B -345M -338M -14.12B -68.94M -59.33M -55.86M -50.9M -95.23M -6.56B -95.61M -662M -256M -3.34B -259M -253M -10.59B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
10/09/26 USD 5.880 +2.62% 1,344,879
09/09/26 USD 5.730 +32.03% 54,319,719
08/09/26 USD 4.340 -7.07% 2,268,609
04/09/26 USD 4.670 +1.52% 2,239,733
03/09/26 USD 4.600 +3.37% 4,425,604
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
5.730USD
Average target price
12.82USD
Spread / Average Target
+123.80%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!